The immuno-oncological challenge of COVID-19

Lisa Derosa; Cléa Melenotte; Franck Griscelli; Bertrand Gachot; Aurélien Marabelle; Guido Kroemer; Laurence Zitvogel

doi:10.1038/s43018-020-00122-3

The immuno-oncological challenge of COVID-19

Lisa Derosa, Cléa Melenotte, Franck Griscelli, Bertrand Gachot, Aurélien Marabelle, Guido Kroemer, Laurence Zitvogel

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

95 Citations (Scopus)

Résumé

Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.

langue originale	Anglais
Pages (de - à)	946-964
Nombre de pages	19
journal	Nature Cancer
Volume	1
Numéro de publication	10
Les DOIs	https://doi.org/10.1038/s43018-020-00122-3
état	Publié - 1 oct. 2020

Accès au document

10.1038/s43018-020-00122-3

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{ae11b0e51ee443bd95583c30aee7bd06,

title = "The immuno-oncological challenge of COVID-19",

abstract = "Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.",

author = "Lisa Derosa and Cl{\'e}a Melenotte and Franck Griscelli and Bertrand Gachot and Aur{\'e}lien Marabelle and Guido Kroemer and Laurence Zitvogel",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Nature America, Inc.",

year = "2020",

month = oct,

day = "1",

doi = "10.1038/s43018-020-00122-3",

language = "English",

volume = "1",

pages = "946--964",

journal = "Nature Cancer",

issn = "2662-1347",

number = "10",

}

TY - JOUR

T1 - The immuno-oncological challenge of COVID-19

AU - Derosa, Lisa

AU - Melenotte, Cléa

AU - Griscelli, Franck

AU - Gachot, Bertrand

AU - Marabelle, Aurélien

AU - Kroemer, Guido

AU - Zitvogel, Laurence

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.

AB - Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85098492434&partnerID=8YFLogxK

U2 - 10.1038/s43018-020-00122-3

DO - 10.1038/s43018-020-00122-3

M3 - Review article

C2 - 35121872

AN - SCOPUS:85098492434

SN - 2662-1347

VL - 1

SP - 946

EP - 964

JO - Nature Cancer

JF - Nature Cancer

IS - 10

ER -